DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main Sells 833 Shares of Axon Enterprise, Inc. (NASDAQ:AXON)

DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main cut its stake in shares of Axon Enterprise, Inc. (NASDAQ:AXON) by 72.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 313 shares of the biotechnology company’s stock after selling 833 shares during the quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main’s holdings in Axon Enterprise were worth $186,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. New Wave Wealth Advisors LLC acquired a new stake in Axon Enterprise in the 4th quarter valued at $40,000. Y.D. More Investments Ltd bought a new position in shares of Axon Enterprise in the fourth quarter valued at $45,000. Stonebridge Financial Group LLC acquired a new position in shares of Axon Enterprise during the fourth quarter valued at about $53,000. GPS Wealth Strategies Group LLC increased its position in shares of Axon Enterprise by 74.1% during the fourth quarter. GPS Wealth Strategies Group LLC now owns 94 shares of the biotechnology company’s stock worth $56,000 after acquiring an additional 40 shares in the last quarter. Finally, Berbice Capital Management LLC acquired a new stake in shares of Axon Enterprise in the 4th quarter worth about $59,000. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Axon Enterprise Price Performance

Axon Enterprise stock opened at $693.10 on Tuesday. The company has a current ratio of 2.96, a quick ratio of 2.63 and a debt-to-equity ratio of 0.32. The business’s 50 day simple moving average is $567.67 and its 200 day simple moving average is $587.57. Axon Enterprise, Inc. has a 12 month low of $273.52 and a 12 month high of $715.99. The company has a market cap of $53.96 billion, a price-to-earnings ratio of 179.10, a PEG ratio of 5.17 and a beta of 1.24.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 EPS for the quarter, beating analysts’ consensus estimates of $1.34 by $0.07. Axon Enterprise had a return on equity of 7.50% and a net margin of 15.37%. The firm had revenue of $603.63 million for the quarter, compared to analysts’ expectations of $585.67 million. During the same quarter in the prior year, the firm earned $1.15 EPS. The business’s revenue for the quarter was up 31.3% compared to the same quarter last year. Sell-side analysts forecast that Axon Enterprise, Inc. will post 5.8 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have commented on the company. Needham & Company LLC boosted their price objective on Axon Enterprise from $600.00 to $750.00 and gave the stock a “buy” rating in a report on Thursday, May 8th. The Goldman Sachs Group increased their price target on Axon Enterprise from $500.00 to $700.00 and gave the company a “buy” rating in a research report on Monday, January 27th. Barclays raised their price objective on Axon Enterprise from $726.00 to $735.00 and gave the company an “overweight” rating in a research note on Friday. Craig Hallum downgraded shares of Axon Enterprise from a “buy” rating to a “cautious” rating in a report on Monday, March 10th. Finally, JMP Securities reissued an “outperform” rating on shares of Axon Enterprise in a research report on Tuesday, February 4th. One analyst has rated the stock with a sell rating, one has issued a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat.com, Axon Enterprise has a consensus rating of “Moderate Buy” and an average price target of $640.91.

Insider Buying and Selling at Axon Enterprise

In other news, CEO Patrick W. Smith sold 10,000 shares of the company’s stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $540.99, for a total transaction of $5,409,900.00. Following the sale, the chief executive officer now directly owns 3,063,982 shares in the company, valued at $1,657,583,622.18. This represents a 0.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Jeri Williams sold 307 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $552.72, for a total transaction of $169,685.04. Following the completion of the transaction, the director now owns 1,627 shares of the company’s stock, valued at $899,275.44. This trade represents a 15.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 4.40% of the company’s stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.